Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points
Key takeaways
- TEZSPIRE shows strong efficacy in Phase 3, paving the way for approval and market entry.
- 64.8% histologic remission (210 mg)
- 68.9% histologic remission (420 mg)
- 3.5% remission (placebo)
What happened
Amgen and AstraZeneca released full Phase 3 CROSSING trial results for TEZSPIRE (tezepelumab‑ekko), showing the 210 mg dose achieved 64.8% histologic remission and the 420 mg dose 68.9% at week 24, compared with 3.5% on placebo. The drug also lowered dysphagia symptoms by 18.8 points (210 mg) and 22.0 points (420 mg) versus 14.7 points for placebo.
Why it matters
The data confirm TEZSPIRE’s effectiveness in treating eosinophilic esophagitis, a chronic condition with limited options. High remission rates and symptom relief could position the drug as a leading therapy, potentially expanding its market share and supporting future pricing and reimbursement negotiations.
Short-term and longer-term
Short-term. Over the next few days, watch for the FDA’s response and any pricing guidance.
Longer-term. In the coming months, the focus will shift to commercial rollout, reimbursement strategy, and potential market penetration against existing therapies.